Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Fetsund – page 7

607 clinical trials in Fetsund, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Fetsund at a glance
607
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

607 trials in Fetsund

Open in trial search

Long‑Term Safety and Efficacy of Infigratinib in Children with Hypochondroplasia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

A study to evaluate the safety and effectiveness of AAVB-039 in patients with Stargardt disease

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:COMBINATION OF TWO ADENO-ASSOCIATED VIRAL VECTORS OF SEROTYPE 8 CONTAINING THE 5'- AND THE 3'- HALF CODING SEQUENCES OF HUMAN ABCA4 FUSED TO INTEINS
  • Sponsor:Aavantgarde Bio S.r.l.

Endometrial cancer+2

Recruiting

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Paclitaxel
  • Sponsor:Genmab A/S

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Evaluation of Safety and Efficacy of MK-2870 and Paclitaxel in Second-Line Treatment of Advanced/Metastatic Gastroesophageal Adenocarcinoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

Study of GSK6042981 compared to sunitinib for patients with gastrointestinal stromal tumors that spread or cannot be removed after imatinib treatment

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Sunitinib
  • Sponsor:Glaxosmithkline Research & Development Limited

A Study of Enlicitide for Safety and Effectiveness in Children and Adolescents with Heterozygous Familial Hypercholesterolemia

Investigational
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC

A study testing the safety and effectiveness of infigratinib compared to placebo in infants and young children with achondroplasia

Investigational
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Carfilzomib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of glepaglutide compared to placebo for patients with short bowel syndrome with intestinal failure

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Glepaglutide
  • Sponsor:Zealand Pharma A/S

A study of bleximenib combined with intensive chemotherapy for adults with newly diagnosed acute myeloid leukemia with specific genetic changes.

Investigational
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bleximenib
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

A study on the long-term effectiveness and safety of nine-valent human papillomavirus vaccine in women aged 16 to 26 years for prevention of cervical cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · Healthy volunteers
  • Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.